These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 2896069)
1. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Slovak ML; Hoeltge GA; Dalton WS; Trent JM Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069 [TBL] [Abstract][Full Text] [Related]
2. Cytogenetic alterations associated with the acquisition of doxorubicin resistance: possible significance of chromosome 7 alterations. Slovak ML; Hoeltge GA; Trent JM Cancer Res; 1987 Dec; 47(24 Pt 1):6646-52. PubMed ID: 3677098 [TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms. Slovak ML; Coccia M; Meltzer PS; Trent JM Anticancer Res; 1991; 11(1):423-8. PubMed ID: 1673331 [TBL] [Abstract][Full Text] [Related]
4. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962 [TBL] [Abstract][Full Text] [Related]
5. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Politi PM; Arnold ST; Felsted RL; Sinha BK Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771 [TBL] [Abstract][Full Text] [Related]
7. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431 [TBL] [Abstract][Full Text] [Related]
8. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance. Politi PM; Sinha BK Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628 [TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416 [TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359 [TBL] [Abstract][Full Text] [Related]
11. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875 [TBL] [Abstract][Full Text] [Related]
12. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Harker WG; Sikic BI Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002 [TBL] [Abstract][Full Text] [Related]
13. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Ogretmen B; McCauley MD; Safa AR Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006 [TBL] [Abstract][Full Text] [Related]
15. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825 [TBL] [Abstract][Full Text] [Related]
16. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells. Yang LY; Trujillo JM; Su YZ Anticancer Res; 1992; 12(2):473-9. PubMed ID: 1349796 [TBL] [Abstract][Full Text] [Related]
17. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056 [TBL] [Abstract][Full Text] [Related]
18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Dalton WS; Durie BG; Alberts DS; Gerlach JH; Cress AE Cancer Res; 1986 Oct; 46(10):5125-30. PubMed ID: 2875788 [TBL] [Abstract][Full Text] [Related]
20. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]